CD37 and neoplasm: Even though Ramos cells had a higher expression of CD20 than CD37, the absorbed doses to tumor for 177Lu-HH1 and 177Lu-rituximab were similar, which might be related to the higher internalization of the CD37-HH1 complex than of the CD20-rituximab, as observed in vitro.